title: Novel OK-432-conjugated tumor vaccines induce tumor-specific immunity against murine tongue cancer.
abstract: Priming with tumor antigens is one of the most important strategies in cancer immunotherapy. To enhance tumor antigenicity, OK-432, a streptococcal preparation, was coupled to squamous cell carcinoma (KLN-205) by means of a 0.2% glutaraldehyde method. The purpose of this study was to investigate whether OK-432-conjugated tumor vaccines could induce tumor-specific immunity. Our originally developed mouse tongue cancer model was used throughout this work for the analysis of antitumor effects. Prepared OK-432-conjugated KLN-205 vaccines were immunized 3 times to DBA/2 mice. The results showed that the KLN-205 vaccines induced cytolytic activity and strongly suppressed both KLN-205 tumor incidence and growth, and survival of the mice was improved. Moreover, the histological results showed that a greater number of lymphocytes had infiltrated around tumor cells by 24 hours after tumor inoculation in the vaccine group. These results suggest that immunizations with KLN-205 vaccines increase the antitumor effects against tongue cancer.
authors.affiliation: Department of Oral and Maxillofacial Surgery, Yokohama City University School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan.
authors.forename: X
authors.initials: X
authors.lastname: Li
authors.forename: H
authors.initials: H
authors.lastname: Bukawa
authors.forename: M
authors.initials: M
authors.lastname: Hirota
authors.forename: Y
authors.initials: Y
authors.lastname: Tsuyuki
authors.forename: S
authors.initials: S
authors.lastname: Omura
authors.forename: K
authors.initials: K
authors.lastname: Fujita
mesh_terms: D000818:Animals; D000951:Antigens, Neoplasm / Q000276:immunology; D000970:Antineoplastic Agents / Q000276:immunology*; D019496:Cancer Vaccines; D002294:Carcinoma, Squamous Cell / Q000276:immunology / Q000473:pathology / Q000517:prevention & control*; D004195:Disease Models, Animal; D005260:Female; D007114:Immunization; D008214:Lymphocytes / Q000276:immunology; D051379:Mice; D008811:Mice, Inbred DBA; D010844:Picibanil / Q000276:immunology*; D015996:Survival Rate; D014062:Tongue Neoplasms / Q000276:immunology / Q000473:pathology / Q000517:prevention & control*; D018074:Vaccines, Conjugate
chemical_list: D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents; D019496:Cancer Vaccines; D018074:Vaccines, Conjugate; D010844:Picibanil